Edition:
United Kingdom

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

20.25HKD
20 Apr 2018
Change (% chg)

HK$-0.35 (-1.70%)
Prev Close
HK$20.60
Open
HK$20.60
Day's High
HK$21.30
Day's Low
HK$19.90
Volume
38,968,665
Avg. Vol
24,518,647
52-wk High
HK$23.45
52-wk Low
HK$10.44

Select another date:

Wed, Apr 18 2018

BRIEF-CSPC Pharmaceutical Announces A Product Licensing Agreement

* UNIT ENTERED PRODUCT LICENSING AGREEMENT WITH GALAXY BIO, INC. FOR LICENSING & COMMERCIALIZATION OF "PACLITAXEL FOR INJECTION"

BRIEF-CSPC Pharmaceutical Group Says Cancer Drug Approved By China FDA

* "VINORELBINE TARTRATE LIPOSOME INJECTION" GRANTED CLINICAL TRIAL APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION OF PRC Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group's Drug Gets Approval By China FDA

* GRANTED APPROVAL BY CHINA FDA FOR PASSING CONSISTENCY OF QUALITY AND EFFICACY EVALUATION OF GENERIC DRUGS

BRIEF-CSPC Pharmaceutical Group Says ‍Cancer Drug Granted Drug Clinical Trial Approval By China FDA

* ‍CANCER DRUG DEVELOPED BY WUHAN YZY BIOPHARMA​ GRANTED DRUG CLINICAL TRIAL APPROVAL BY CHINA FDA Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group Announces Drug Registration Approval Of "Paclitaxel For Injection (Albumin-Bound)"

* ‍"PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​

* ‍GROUP'S GASTRIC CANCER DRUG "DP303C" WAS GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA​ Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group Says Unit's Listing Application To CSRC Was Accepted

* CSPC XNW SUBMITTED APPLICATION TO CSRC FOR PROPOSED A SHARE LISTING ON CHINEXT OF SZSE & RECEIVED NOTICE OF ACCEPTANCE

BRIEF-CSPC Pharmaceutical Group Appoints ‍Li Chunlei As Executive Director ​

* ‍LI CHUNLEI WAS APPOINTED AS AN EXECUTIVE DIRECTOR OF COMPANY WITH EFFECT FROM 12 DECEMBER 2017.​

BRIEF-CSPC Pharmaceutical Group announces change of shareholdings of substantial shareholder

* ‍Massive Giant Group transferred approximately 6.78% of total issued shares to Common Success International​ Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group posts 9-month profit attributable of HK$‍2.04​ bln

* 9-month profit attributable HK$‍2.04​ billion versus HK$1.57 billion

Select another date: